Effect of Thyroxine Replacement on Creatinine, Insulin-Like Growth Factor 1, Acid-Labile Subunit, and Vascular Endothelial Growth Factor

Clinical Chemistry

Volumn 50, Issue 1, 2004, Pages 228-231

  Schmid, Christoph ^a   Brändie, Michael ^a   Zwimpfer, Cornelia ^a   Zapf, Jürgen ^a   Wiesli, Peter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; ACID LABILE SUBUNIT; ANTIHYPERTENSIVE AGENT; CREATININE; N(G) NITROARGININE METHYL ESTER; SOMATOMEDIN C; THYROXINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; EUTHYROIDISM; FEMALE; HEART RATE; HEMOCONCENTRATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; INFORMED CONSENT; KIDNEY BLOOD FLOW; LABORATORY TEST; MALE; MEASUREMENT; PATIENT; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS;

ADULT; CARRIER PROTEINS; CREATININE; FEMALE; GLYCOPROTEINS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; THYROXINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1642574217     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.021022     Document Type: Article

References (30)

1. Lekakis J, Papamichael C, Alevizaki M, Piperingos G, Marafelia P, Mantzos J, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997;7:411-4.
2. Montenegro J, Gonzalez O, Saracho R, Aguirre R, Gonzalez O, Martinez I. Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996;27:195-8.
3. Saito I, Ito K, Saruta T. Hypothyroidism as a cause of hypertension. Hypertension 1983;5:112-5.
4. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med 1999;159:79-82.
5. Allon M, Harrow A, Pasque CB, Rodriguez M. Renal sodium and water handling in hypothyroid patients: the role of renal insufficiency. J Am Soc Nephrol 1990;1:205-10.
6. Baxter RC, Brown AS, Turtle JR. Radioimmunoassay for somatomedin C: comparison with radioreceptor assay in patients with growth-hormone disorders, hypothyroidism, and renal failure. Clin Chem 1982;28:488-95.
7. Copeland KC, Nair KS. Recombinant human insulin-like growth factor-I increases forearm blood flow. J Clin Endocrinol Metab 1994;79:230-2.
8. Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A 1989;86:2868-72.
9. Guler HP, Eckardt KU, Zapf J, Bauer C, Froesch ER. Insulin-like growth factor I increase glomerular filtration rate and renal plasma flow in man. Acta Endocrinol (Copenh) 1989;121:101-6.
10. Klanke B, Simon M, Rockl W, Weich HA, Stolte H, Grone HJ. Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant 1998;13:875-85.
11. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001;98:2604-9.
12. Gerber HP, McMurtrey A, Kowalski J, Van M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43.
13. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999;274:33057-63.
14. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002;87:4238-44.
15. Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002;87:1737-42.
16. Zapf J, Walter H, Froesch ER. Radioimmunological determination of insulin-like growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest 1981;68:1321-30.
17. Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone-and IGF-binding proteins. J Clin Endocrinol Metab 1993;76:950-5.
18. Valcavi R, Dieguez C, Preece M, Taylor A, Portioli I, Scanlon MF. Effect of thyroxine replacement therapy on plasma insulin-like growth factor 1 levels and growth hormone responses to growth hormone releasing factor in hypothyrold patients. Clin Endocrinol (Oxf) 1987;27:85-90.
19. Chernausek SD, Turner R. Attenuation of spontaneous, nocturnal growth hormone secretion in children with hypothyroidism and its correlation with plasma insulin-like growth factor I concentrations. J Pediatr 1989;114:968-72.
20. Giustina A, Wehrenberg WB. Influence of thyroid hormones on the regulation of growth hormone secretion. Eur J Endocrinol 1995;133:646-53.
21. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598-604.
22. Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int 1991;39:333-5.
23. Diekman MJ, Harms MP, Endert E, Wieling W, Wlersinga WM. Endocrine factors related to changes in total peripheral vascular resistance after treatment of thyrotoxic and hypothyroid patients. Eur J Endocrinol 2001;144:339-46.
24. Giannattasio C, Rivolta MR, Failla M, Mangoni AA, Stella ML, Mancia G. Large and medium sized artery abnormalities in untreated and treated hypothyroidism. Eur Heart J 1997;18:1492-8.
25. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002;87:1996-2000.
26. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001;47:617-23.
27. Sullivan PS, McDonald TP. Thyroxine suppresses thrombocytopoiesis and stimulates erythropoiesis in mice. Proc Soc Exp Biol Med 1992;201:271-7.
28. Mamiya S, Hagiwara M, Inoue S, Hidaka H. Thyroid hormones inhibit platelet function and myosin light chain kinase. J Biol Chem 1989;264:8575-9.
29. Simon M, Grone HJ, Johren O, Kullmer J, Plate KH, Risau W, Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240-50.
30. Hirschberg R, Kopple JD, Blantz RC, Tucker BJ. Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 1991;87:1200-6.